Human papillomavirus genotype distribution in cervical cancer in India: Results from a multi-center study

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 1, 2009, Pages 27-34

  Basu, Partha ^a   Roychowdhury, Soma ^b   Bafna, Uttam Das ^c   Chaudhury, Santanu ^d   Kothari, Sarita ^d   Sekhon, Rupinder ^e   Saranath, Dhananjaya ^f   Biswas, Sutapa ^b   Gronn, Petter ^g   Silva, Ivan ^g   Siddiqi, Maqsood ^b   Ratnam, Sam ^h  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Cancer Foundation of India   (India)

^c Department of Pathology   (India)

^d RST Cancer Hospital   (India)

^e Department of Oncology   (India)

^f RELIANCE LIFE SCIENCES PVT LTD   (India)

^g St John's ^*

^h Public Health Laboratory   (Canada)

Author keywords

Cervical cancer; HPV genotype; India; PreTect HPV proofer

Indexed keywords

EID: 67650889075     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bao YP, Li N, Smith JS, Qiao YL, ACCPAB members (2008). Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer, 18, 71-9.
2. Bhatla N, Dar L, Patro ARK, et al. (2006). Human papillomavirus type distribution in cervical cancer in Delhi, India. Int J Gynecol Pathol, 25, 393-402.
3. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. (2008). A meta-analysis of human papillomavirus type-distribution in women from South Asia: Implications for vaccination. Vaccine, 26, 2811-7.
4. Chopra R. (2001). The Indian scene. J Clin Oncol, 19, 106s-11s
5. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88, 63-73.
6. Clifford GM, Rana RK, Franceschi S, et al. (2005). Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev, 14, 1157-64.
7. Clifford G, Franceschi S, Mireia D, Munoz N, Lina Villa L. (2006). HPV type distribution in women with and without cervical neoplastic diseases. Vaccine, 24 S3, 26-34.
8. Cuschieri KS, Whitley MJ, Cubie HA. (2004). Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol, 73, 65-70.
9. Franceschi S, Rajkumar T, Vaccarella S, et al. (2003). Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. Int J Cancer, 107, 127-33.
10. FUTURE II Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Eng J Med, 356, 1915-27.
11. Giannoudis A, Herrington CS. (2001). Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol, 193, 295-302.
12. Hong D, Ye F, Chen H, et al. (2008). Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang province, China. Int J Gynecol Cancer, 18, 104-9.
13. Insinga RP, Liaw Kl, Johnson LG, Madeleine MM. (2008). A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev, 17, 1611-22.
14. Klug SJ, Molijin A, Schopp B, et al. (2008). Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol, 80, 1264-74.
15. Kraus I, Molden T, Holm R, et al. (2006). Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol, 44, 1310-7.
16. Lie AK, Risberg B, Borge B, et al. (2005). DNA- versus RNAbased methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol, 97, 908-15.
17. Molden T, Kraus I, Karlsen F, et al. (2005). Comparison of human papillomavirus messenger RNA and DNA detection: A crosssectional study of 4,136 women > 30 years of age with a 2-year follow up of high grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev, 14, 367-72.
18. Molden T, Kraus I, Skomedal H, Nordstrom T, Karlsen F. (2007). Pre Tect TM HPV-Proofer: Real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods, 142, 204-12.
19. Munirajan AK, Kannan K, Bhuvarahamurthy V, et al. (1998). The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India. Gynecol Oncol, 69, 205-9.
20. Munoz N, Bosch FX, de Sanjose S, et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
21. Munoz N, Bosch FX, Castellsague X, et al. (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 111, 278-85.
22. Paavonen J, Jenkins D, Bosch FX, et al. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women. An interim analysis of a phase III double-blind randomized controlled trial. Lancet, 369, 2161-70.
23. Peedicayil A, Abraham P, Sathish N, et al. (2006). Human papillomavirus genotypes associated with cervical neoplasia in India. Int J Gynecol Cancer, 16, 1591-5.
24. Pillai MR, Sreevidya S, Pollock BH, Jayaprakash PG, Herman B. (2002). Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical caner. Gynecol Oncol, 87, 268-73.
25. Pretet JL, Jacquard AC, Carcopino X, et al. (2008). Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer, 122, 428-32.
26. Sanger F, Nicklen S, Coulson AR. (1977). DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA, 74, 5463-7.
27. Saranath D, Khan Z, Tandle AT, et al. (2002). HPV 16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol, 86, 157-62.
28. Sathish N, Abraham P, Peedicayil A, et al. (2004). HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol, 31, 204-9.
29. Smith JS, Lindsay L, Hoots B, et al. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer, 121, 621-32.
30. Sotlar K, Stubner A, Diemer D, et al. (2004). Detection of highrisk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol, 74, 107-16.
31. Sowjanya AP, Jain M, Poli UR, et al. (2005). Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis, 5, 116.
32. Villa L. (2007). Quadrivalent human papillomavirus (HPV) type 6/11/16/18 L1 virus-like particle vaccine: First analysis of cross-protection against cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18 (Abst). Eurogin.
33. Walboomers JMM, Jacobs MV, Manos MM, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.